Lerodalcibep (Lerochol) for Hypercholesterolemia
The Medical Letter on Drugs and Therapeutics · 11.05.2026 · 68 (1754) · 71-75
DOI: 10.58347/tml.2026.1754a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 11.05.2026.
Abstract (Originalsprache)
The FDA has approved lerodalcibep (Lerochol – Lib Therapeutics), a subcutaneously injected proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep is the fourth subcutaneously injected PCSK9-directed therapy to be approved in the US; the monoclonal antibodies alirocumab (Praluent) and evolocumab (Repatha) and the small interfering RNA inclisiran (Leqvio) were approved earlier.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Lerodalcibep (Lerochol) for Hypercholesterolemia. The Medical Letter on Drugs and Therapeutics, 68(1754), 71-75. https://doi.org/10.58347/tml.2026.1754a
Vancouver
Lerodalcibep (Lerochol) for Hypercholesterolemia. The Medical Letter on Drugs and Therapeutics. 2026;68(1754):71-75. doi:10.58347/tml.2026.1754a
BibTeX
@article{euvimed2026,
title = {Lerodalcibep (Lerochol) for Hypercholesterolemia},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1754},
pages = {71--75},
doi = {10.58347/tml.2026.1754a}
}
EUVIMED